SCHEMBL480113

SCHEMBL480113

COC(=O)c1cccc(N)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
CYP1A2 P05177 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
GAA P10253 1/20 0.51
RECQL P46063 1/20 0.51
TP53 P04637 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 2/20 0.46
PKM P14618 1/20 0.46
HSD17B10 Q99714 2/20 0.44
CFTR P13569 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29918942 1.00 MAPT (0.51) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL6674420 0.98 MAPT (0.50) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL5740003 0.93 KDM4E (0.52) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL69653 0.86 MAPT (0.64) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL17276045 0.81 MAPT (0.55) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL465841 0.80 CYP1A2 (0.77) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL29677764 0.80 CYP1A2 (0.77) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL23037197 0.80 MAPT (0.54) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL29595815 0.80 MAPT (0.54) MAPTCYP1A2SMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL6741600 0.79 CYP1A2 (0.74) MAPTCYP1A2SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039329-A Binuclear rare earth complex, preparation method and application 西安石油大学 2024-11-29 CN claimed
CN-111521601-B Application of ratio-type fluorescent polymer hydrogel in seafood freshness detection 中国科学院宁波材料技术与工程研究所 2022-01-25 CN claimed
CN-111808079-A Indole ASK1 small molecule inhibitor and preparation method and application thereof 中国药科大学 2020-10-23 CN claimed
CN-111521601-A Application of ratio-type fluorescent polymer hydrogel in seafood freshness detection 中国科学院宁波材料技术与工程研究所 2020-08-11 CN claimed
CN-109608441-A A kind of synthesis technology of ASK1 inhibitor 都创(上海)医药科技有限公司 2019-04-12 CN claimed
EP-4003988-B1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS SERVIER LAB (FR) 2026-05-20 EP disclosed
EP-4096662-B1 PROCESS FOR PREPARATION OF LASMIDITAN ALIVUS LIFE SCIENCES LTD (IN) 2026-03-25 EP disclosed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 EP disclosed
WO-2025245472-A1 COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES REMIX THERAPEUTICS INC. (US) 2025-11-27 WO disclosed
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists Nimbus Saturn, Inc. (US) 2025-11-11 US disclosed
WO-2025226545-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2025-10-30 WO disclosed
WO-2025227032-A1 METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES REMIX THERAPEUTICS INC. (US) 2025-10-30 WO disclosed
US-4689342-A MITICIDES, NEMATOCIDES ROUSSEL UCLAF (FR) 1987-08-25 US disclosed
US-4596869-A Pyridinyl and pyrimidinyl derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-06-24 US disclosed
EP-0110769-B1 ESTERS DERIVED FROM 2,2-DIMETHYLCYCLOPROPANE-CARBOXYLIC ACIDS AND BIARYL ALCOHOLS, PROCESS FOR THEIR PREPARATION, THEIR USE AS PARASITICIDES AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1986-03-05 EP disclosed
US-4528296-A Derivatives of aminopyridinecarboxylic acids and pharmaceutical compositions containing them SIMES, SOCIETA ITALIANA MEDICINALLE SINTETICI (IT) 1985-07-09 US disclosed
EP-0110484-A1 Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them Simes S.p.A. (IT) 1984-06-13 EP disclosed
US-4447256-A POSTEMERGENCE HERBICIDE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1984-05-08 US disclosed
US-4395411-A ANTIBIOTICS; BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-07-26 US disclosed
US-4267176-A Amino or acylamino-substituted pyrimidinyl cephalosporanic acid derivatives and pharmaceutical compositions thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists PDXK, HIPK1, HIPK3 MAPT 3393/4885CYP1A2 3917/4885SMN1; SMN2 3266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.